公司概述
Cosmos Health Inc. operates as a manufacturer, developer, and trader of branded nutraceutical products with a geographic footprint spanning Greece, Croatia, Bulgaria, the United Arab Emirates, the United Kingdom, and Cyprus. The company's portfolio encompasses a diverse range of healthcare offerings, including prescription medications, over-the-counter drugs, medical devices, food supplements, nutraceuticals, and cosmetics, positioning it within the broader healthcare sector. Specifically, the firm functions in the medical distribution industry, a segment characterized by the supply chain logistics and distribution of medical goods to various healthcare providers and retailers. As of the latest reporting period, the company holds a market capitalization of $10.83M and generated annual revenue of $59.79M, supporting an operational workforce of 149 employees. These valuation and revenue figures indicate that Cosmos Health Inc. is a micro-cap entity with a relatively small market presence compared to large-cap peers, suggesting a business model that may rely on high growth potential or niche market penetration rather than established scale economies to drive shareholder value.
财务健康
The company reported revenue of $59.79M for the trailing twelve months, yet recorded a net income of $-18,542,138 and an EBITDA of $-12,621,250, revealing a significant disparity between top-line sales and bottom-line profitability. This substantial gap between revenue and net income highlights a challenging cost structure where operating expenses, including cost of goods sold and administrative costs, are consuming a majority of the generated sales, resulting in a loss on every dollar of revenue. Furthermore, the free cash flow stands at $-5,310,300, indicating that the company is currently burning cash, which severely limits its financial flexibility and ability to fund organic growth or weather economic downturns without external capital injections. Profitability metrics reflect this struggle, with a gross margin of 11.4%, an operating margin of -10.6%, and a profit margin of -31.0%, demonstrating that the company fails to cover its operating costs and incurs significant losses relative to its sales volume. On the balance sheet, the company holds $922,619 in cash but carries $21.07M in debt, resulting in a debt-to-equity ratio of 91.08%, which signifies a highly leveraged position where debt obligations substantially exceed equity capitalization. Liquidity concerns are further underscored by a current ratio of 0.99, suggesting that the company's current assets are insufficient to cover its current liabilities without relying on external financing or asset liquidation. Additionally, the return on equity is -63.8% and the return on assets is -13.0%, metrics that collectively reveal a lack of management effectiveness in generating positive returns on the capital employed by shareholders and creditors.
估值评估
Valuation multiples for Cosmos Health Inc. present a complex picture due to its negative earnings, with a trailing P/E ratio of N/A and a forward P/E of -2.64. The divergence between a non-existent trailing P/E and a negative forward P/E implies that analysts or the market is pricing in a potential future earnings recovery, although the negative forward P/E itself suggests that expected future earnings are also negative or that the current price is not yet reflecting a turnaround. The price-to-book ratio stands at 0.40, indicating that the stock trades at a significant discount to its book value, which often occurs in distressed situations or for companies with heavy intangible assets or temporary operational issues. Alternative valuation metrics such as the price-to-sales ratio of 0.18 and an EV/EBITDA of -2.40 further suggest that the market is not assigning a traditional earnings-based premium to the company, but rather valuing it based on sales volume or asset backing. Price volatility is evident from the 52-week range, with the stock trading between a low of $0.28 and a high of $1.32, providing context for the current trading price relative to its historical extremes. The beta of 4.46 indicates that the stock's price is highly sensitive to market movements, exhibiting volatility that is more than four times that of the broader market, which amplifies both potential gains and losses for holders of this highly speculative asset.
Growth & Income
Cosmos Health Inc. demonstrated robust top-line expansion with a revenue growth of 37.9% year-over-year, while earnings growth is N/A due to the company's current unprofitability. The absence of positive earnings growth relative to revenue growth implies that the company is prioritizing market share expansion or cost restructuring at the expense of immediate profitability, a common strategy in the early stages of business development but one that carries inherent risk. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, indicating that all available cash flow is retained within the business rather than distributed to shareholders. This reinvestment approach is typical for micro-cap companies that lack the cash reserves to support dividend payments and instead focus on funding operations or growth initiatives from retained earnings. Consequently, the overall growth and income profile of Cosmos Health Inc. is defined by aggressive revenue expansion coupled with significant operational losses and no current income distribution, presenting a high-risk, high-reward dynamic typical of early-stage or turnaround healthcare entities.